Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting the leukemia microenvironment.

Marina Konopleva1, Michael Andreeff

  • 1Section of Molecular Hematology and Therapy and Department of Stem Cell Transplantation and Cellular Therapies, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. mkonople@mdanderson.org

Current Drug Targets
|June 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.

Haematologica·2022
Same author

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.

American journal of hematology·2022
Same author

Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.

Nature communications·2022
Same author

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatment.

Leukemia & lymphoma·2022
Same author

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.

American journal of hematology·2022
Same author

Novel UHRF1-MYC Axis in Acute Lymphoblastic Leukemia.

Cancers·2022
Same journal

Barbatolic Acid Prevents Tau and Amylin Interaction and Stimulates the Growth of Acetylated Microtubules in Cell Culture.

Current drug targets·2026
Same journal

Harnessing HIF-1α for Diabetic Wound Healing: From Molecular Insights to Therapeutic Strategies.

Current drug targets·2026
Same journal

Extracellular Vesicles from Mesenchymal Stem Cells Alleviate Spinal Cord Injury via the miR-486-5p/PTEN/PI3K/AKT Pathway.

Current drug targets·2026
Same journal

Improving B-cell Linear Epitope Prediction <i>via</i> Multiple Feature Fusion and an Integrated Machine Learning Algorithm.

Current drug targets·2026
Same journal

Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis.

Current drug targets·2026
Same journal

Epitranscriptomics in Breast Cancer: The Unveiled Role of RNA Modifications.

Current drug targets·2026
See all related articles

The bone marrow microenvironment influences leukemia development and drug resistance. Targeting this microenvironment may improve therapies for hematological malignancies.

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Normal blood cell production (hematopoiesis) relies on bone marrow microenvironment interactions.
  • Leukemic cells interact with bone marrow stromal, osteoblast, and endothelial cells.

Purpose of the Study:

  • To review the influence of the bone marrow microenvironment on leukemic cell phenotype evolution.
  • To explore how microenvironmental niches may protect leukemic cells from chemotherapy and promote drug resistance.

Main Methods:

  • Literature review of studies on microenvironment-leukemia interactions.
  • Analysis of proposed mechanisms for chemoresistance development within specific niches.
  • Discussion of emerging therapeutic strategies targeting these interactions.

Related Experiment Videos

Main Results:

  • The bone marrow microenvironment plays a critical role in leukemic cell survival and drug resistance.
  • Specific bone marrow niches can act as sanctuaries for leukemic cell subpopulations.
  • Leukemic cells can acquire a chemoresistant phenotype through interactions with the microenvironment.

Conclusions:

  • The crosstalk between leukemia cells and the bone marrow microenvironment is crucial for disease progression and treatment failure.
  • Targeting the stroma-leukemia interaction offers a promising therapeutic avenue.
  • Developing strategies to disrupt these interactions could enhance chemotherapy efficacy and overcome chemoresistance in hematological malignancies.